Skip to main content
. 2025 May 17;32:101878. doi: 10.1016/j.mtbio.2025.101878

Fig. 6.

Fig. 6

Therapeutic evaluation of mPEG-CDM-GsEVs-DOX in GL261 glioma. (a) Experimental timeline illustrating GL261 cell implantation, DOX treatment regimen, and tissue collection for analysis. (b) Kaplan-Meier survival curves of glioma-bearing mice treated with PBS (control), free DOX, GsEVs-DOX, or mPEG-CDM-GsEVs-DOX (n = 15). (c) Representative fluorescence images of DOX (green) in brain tissues from different treatment groups. Scale bar: 50 μm. (d) Statistical analysis of MFI from (c) (n = 5). (e) Representative gross brain images and HE-stained sections showing tumor burden in each treatment group. (f) Statistical analysis of tumor volume from (e) (n = 5). (g) Representative Ki67-stained brain sections evaluating tumor proliferative activity in different treatment groups. Scale bar: 50 μm. (h) Statistical analysis of Ki67 mean density from (g) (n = 5). Data are shown as mean ± SD. ∗∗p < 0.01; ∗∗∗p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)